Human Oncology & Pathogenesis Program

The Sarat Chandarlapaty Lab

Research

Pictured: Sarat Chandarlapaty
Sarat Chandarlapaty, MD, PhD
Naddisy Foundation Chair in Breast Cancer Research

My lab focuses on understanding the regulation of growth factor signal transduction pathways that are aberrantly activated in cancers, with a focus on those implicated in breast cancer pathogenesis.

View Lab Overview

Chandarlapaty Lab Team

Publications Highlights

Will M, Liang J, Metcalfe C, Chandarlapaty S. Therapeutic resistance to anti-oestrogen therapy in breast cancer. Nat Rev Cancer. 2023 Oct;23(10):673-685. doi: 10.1038/s41568-023-00604-3. Epub 2023 Jul 27. Review. PubMed PMID: 37500767; PubMed Central PMCID: PMC10529099.

Li Q, Jiang B, Guo J, Shao H, Del Priore IS, Chang Q, Kudo R, Li Z, Razavi P, Liu B, Boghossian AS, Rees MG, Ronan MM, Roth JA, Donovan KA, Palafox M, Reis-Filho JS, de Stanchina E, Fischer ES, Rosen N, Serra V, Koff A, Chodera JD, Gray NS, Chandarlapaty S. INK4 Tumor Suppressor Proteins Mediate Resistance to CDK4/6 Kinase Inhibitors. Cancer Discov. 2022 Feb;12(2):356-371. doi: 10.1158/2159-8290.CD-20-1726. Epub 2021 Sep 20. PubMed PMID: 34544752; PubMed Central PMCID: PMC8831444.

Razavi P, Dickler MN, Shah PD, Toy W, Brown DN, Won HH, Li BT, Shen R, Vasan N, Modi S, Jhaveri K, Caravella BA, Patil S, Selenica P, Zamora S, Cowan AM, Comen E, Singh A, Covey A, Berger MF, Hudis CA, Norton L, Nagy RJ, Odegaard JI, Lanman RB, Solit DB, Robson ME, Lacouture ME, Brogi E, Reis-Filho JS, Moynahan ME, Scaltriti M, Chandarlapaty S. Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors. Nat Cancer. 2020 Apr;1(4):382-393. doi: 10.1038/s43018-020-0047-1. Epub 2020 Mar 23. PubMed PMID: 32864625; PubMed Central PMCID: PMC7450824.

Li Z, Razavi P, Li Q, Toy W, Liu B, Ping C, Hsieh W, Sanchez-Vega F, Brown DN, Da Cruz Paula AF, Morris L, Selenica P, Eichenberger E, Shen R, Schultz N, Rosen N, Scaltriti M, Brogi E, Baselga J, Reis-Filho JS, Chandarlapaty S. Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway. Cancer Cell. 2018 Dec 10;34(6):893-905.e8. doi: 10.1016/j.ccell.2018.11.006. PubMed PMID: 30537512; PubMed Central PMCID: PMC6294301.

Toy W, Shen Y, Won H, Green B, Sakr RA, Will M, Li Z, Gala K, Fanning S, King TA, Hudis C, Chen D, Taran T, Hortobagyi G, Greene G, Berger M, Baselga J, Chandarlapaty S. ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat Genet. 2013 Dec;45(12):1439-45. doi: 10.1038/ng.2822. Epub 2013 Nov 3. PubMed PMID: 24185512; PubMed Central PMCID: PMC3903423. 

View All Publications

People

Pictured: Sarat Chandarlapaty

Sarat Chandarlapaty, MD, PhD

Naddisy Foundation Chair in Breast Cancer Research

  • Physician-scientist Sarat Chandarlapaty studies the regulation of growth factor signaling networks in cancer.
  • MD, Wake Forest School of Medicine
  • PhD, University of North Carolina
[email protected]
Email Address
View physician profile
Physician profile

Members

Yanyan Cai

Senior Research Scientist

Wanyi Chen

WGS Student

Joshua Drago

Assistant Attending

Avantika Gupta
Avantika Gupta

Research Scholar

Catherine Jones

Research Technician

Rei Kudo
Rei Kudo

Research Fellow

Minna Lee

Assistant Attending

Antonio Marra

Research Associate

Samuel Molina

GSK Graduate Student

Sharanya Nag

Research Scholar

Elizabeth O'Connell

Research Technician

Payal Patel

Graduate Student

Hong Shao

Research Lab Manager

Marie Will

Assistant Attending

Lab Alumni
Trusha Bhatt
Trusha Bhatt

Research Technician

Isabella Del Priore
Isabella Del Priore

Research Technician

Madeline Dorso
Madeline Dorso

Graduate Student

Mayur Gadiya
Mayur Gadiya

Graduate Student

Kinisha Gala
Kinisha Gala
Seema Irani
Seema Irani
Jisun Kim

Visiting Investigator

Qing Li
Qing Li

Research Fellow

Zhiqiang Li
Zhiqiang Li

Research Fellow

Bo Liu, Research Associate
Bo Liu

Research Associate

Shraddha Pancholi
Shraddha Pancholi

Research Secretary

Ramya Segu Rajappachetty
Ramya Segu Rajappachetty

Research Technician Sr.

Alison Smith
Alison Smith

Graduate Student

Antonio Strillacci
Antonio Strillacci

Research Fellow

Weiyi Toy
Weiyi Toy

Research Fellow

Sharmeen Uddin
Sharmeen Uddin

Research Technician

ChengCheng Yang
ChengCheng Yang

Graduate Research Assistant

Lab Affiliations

Achievements

Clinical Investigator Award, Damon Runyon Cancer Research Foundation (2012)

Young Investigator Award, American Society of Clinical Oncology (2007)

Fellow in Biomedical Research, The Dana Foundation (2006)

Open Positions

To learn more about available postdoctoral opportunities, please visit our Career Center

To learn more about compensation and benefits for postdoctoral researchers at MSK, please visit Resources for Postdocs

Career Opportunities

Apply now

Get in Touch

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Sarat Chandarlapaty discloses the following relationships and financial interests:

  • AstraZeneca
    Professional Services and Activities
  • Blueprint Medicines
    Professional Services and Activities
  • Casdin Capital, LLC
    Professional Services and Activities
  • Daiichi Sankyo
    Professional Services and Activities
  • eFFECTOR Therapeutics
    Equity; Professional Services and Activities
  • Eli Lilly and Company
    Professional Services and Activities (Uncompensated)
  • Encore Medical Education
    Professional Services and Activities
  • Genesis Therapeutics
    Professional Services and Activities
  • Gerson Lehrman Group
    Professional Services and Activities
  • Novartis
    Professional Services and Activities
  • Nuvalent, Inc.
    Professional Services and Activities
  • Odyssey Biosciences
    Equity; Fiduciary Role / Position; Intellectual Property Rights
  • Prelude Therapeutics
    Professional Services and Activities
  • SAGA Diagnostics
    Professional Services and Activities
  • Springer Nature Limited
    Professional Services and Activities
  • Totus Medicines Inc.
    Equity

The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.


This page and data include information for a specific MSK annual disclosure period (January 1, 2023 through disclosure submission in spring 2024). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].


View all disclosures